MA33502B1 - Composés pyrazolopyrimidine inhibiteurs des jak et procédés - Google Patents
Composés pyrazolopyrimidine inhibiteurs des jak et procédésInfo
- Publication number
- MA33502B1 MA33502B1 MA34594A MA34594A MA33502B1 MA 33502 B1 MA33502 B1 MA 33502B1 MA 34594 A MA34594 A MA 34594A MA 34594 A MA34594 A MA 34594A MA 33502 B1 MA33502 B1 MA 33502B1
- Authority
- MA
- Morocco
- Prior art keywords
- methods
- jak inhibitor
- pyrazolopyrimidine compounds
- disease
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
LA PRÉSENTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE I, DES ÉNANTIOMÈRES, DES DIASTÉRÉOISOMÈRES, DES TAUTOMÈRES OU DES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI, DANS LAQUELLE R1, R2 ET R3 SONT TELS QUE DÉFINIS ICI, QUI SONT UTILES COMME INHIBITEURS D'UNE OU PLUSIEURS PARMI LES JANUS KINASES. L'INVENTION CONCERNE ÉGALEMENT UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN COMPOSÉ DE FORMULE I ET UN TRANSPORTEUR, UN ADJUVANT OU UN VÉHICULE PHARMACEUTIQUEMENT ACCEPTABLE, ET DES PROCÉDÉS DE TRAITEMENT OU DE DIMINUTION DE LA SÉVÉRITÉ D'UNE MALADIE OU D'UN ÉTAT EN RÉPONSE À L'INHIBITION D'UNE ACTIVITÉ DE JANUS KINASE CHEZ UN PATIENT.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22291809P | 2009-07-02 | 2009-07-02 | |
PCT/US2010/040906 WO2011003065A2 (fr) | 2009-07-02 | 2010-07-02 | Composés pyrazolopyrimidine inhibiteurs des jak et procédés |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33502B1 true MA33502B1 (fr) | 2012-08-01 |
Family
ID=43411778
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34594A MA33502B1 (fr) | 2009-07-02 | 2010-07-02 | Composés pyrazolopyrimidine inhibiteurs des jak et procédés |
Country Status (35)
Country | Link |
---|---|
US (5) | US8999998B2 (fr) |
EP (3) | EP2448941B1 (fr) |
JP (4) | JP5769261B2 (fr) |
KR (3) | KR20180108858A (fr) |
CN (2) | CN102482284B (fr) |
AU (1) | AU2010266188B2 (fr) |
BR (1) | BRPI1010197A2 (fr) |
CA (1) | CA2767097A1 (fr) |
CL (1) | CL2012000001A1 (fr) |
CO (1) | CO6491081A2 (fr) |
CR (2) | CR20170115A (fr) |
DK (1) | DK2448941T3 (fr) |
EC (1) | ECSP12011645A (fr) |
ES (1) | ES2657839T3 (fr) |
HR (1) | HRP20180157T1 (fr) |
HU (1) | HUE035537T2 (fr) |
IL (3) | IL217224B (fr) |
IN (1) | IN2012DN00755A (fr) |
LT (1) | LT2448941T (fr) |
MA (1) | MA33502B1 (fr) |
MX (1) | MX2012000169A (fr) |
MY (1) | MY160156A (fr) |
NO (1) | NO2448941T3 (fr) |
NZ (4) | NZ706218A (fr) |
PE (2) | PE20120575A1 (fr) |
PH (1) | PH12015500666A1 (fr) |
PL (1) | PL2448941T3 (fr) |
PT (1) | PT2448941T (fr) |
RS (1) | RS56671B1 (fr) |
RU (2) | RU2675857C2 (fr) |
SG (2) | SG10201509607XA (fr) |
SI (1) | SI2448941T1 (fr) |
UA (1) | UA110324C2 (fr) |
WO (1) | WO2011003065A2 (fr) |
ZA (2) | ZA201200490B (fr) |
Families Citing this family (119)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2700433T3 (es) | 2005-12-13 | 2019-02-15 | Incyte Holdings Corp | Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas Janus |
HUE029236T2 (en) | 2007-06-13 | 2017-02-28 | Incyte Holdings Corp | (R) -3- (4- (7H-Pyrrolo [2,3-d] pyrimidin-4-yl) -1H-pyrazol-1-yl) -3-cyclopentylpropanenitrile Crystalline salts of Janus kinase inhibitor |
PE20131197A1 (es) | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
WO2010135621A1 (fr) | 2009-05-22 | 2010-11-25 | Incyte Corporation | 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- ou heptane-nitrile en tant qu'inhibiteurs de jak |
UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
ES2662588T3 (es) | 2010-03-10 | 2018-04-09 | Incyte Holdings Corporation | Derivados de piperidin-4-IL azetidina como inhibidores de JAK1 |
ES2601004T3 (es) | 2010-04-07 | 2017-02-13 | F. Hoffmann-La Roche Ag | Compuestos pirazol-4-il-heterociclil-carboxamida y métodos de uso |
CN103002875B (zh) | 2010-05-21 | 2016-05-04 | 因塞特控股公司 | Jak抑制剂的局部用制剂 |
CN105367577B (zh) * | 2010-07-13 | 2019-04-23 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
ES2775125T3 (es) | 2010-11-03 | 2020-07-23 | Dow Agrosciences Llc | Composiciones plaguicidas y procedimientos relacionados |
US8609669B2 (en) | 2010-11-16 | 2013-12-17 | Abbvie Inc. | Potassium channel modulators |
AU2011329734B2 (en) | 2010-11-19 | 2015-05-28 | Incyte Holdings Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
WO2012129258A1 (fr) * | 2011-03-22 | 2012-09-27 | Merck Sharp & Dohme Corp. | Inhibiteurs de kinases associées aux récepteurs d'interleukine à base d'amidopyrazole |
US8859549B2 (en) | 2011-05-13 | 2014-10-14 | Abbvie, Inc. | Potassium channel modulators |
MY165963A (en) | 2011-06-20 | 2018-05-18 | Incyte Holdings Corp | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
EP2723746A1 (fr) | 2011-06-22 | 2014-04-30 | Vertex Pharmaceuticals Inc. | Composés inhibiteurs de la kinase atr |
UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
RU2638552C2 (ru) | 2011-09-27 | 2017-12-14 | Ф. Хоффманн-Ля Рош Аг | Пиразол-4-ил-гетероциклил-карбоксамидные соединения и способы применения |
BR112014007622A2 (pt) | 2011-09-30 | 2017-04-04 | Oncodesign Sa | inibidores de flt3 cinase macrocíclicos |
US8937083B2 (en) | 2011-10-26 | 2015-01-20 | DowAgroSciences, LLC | Pesticidal compositions and processes related thereto |
WO2013086229A1 (fr) | 2011-12-07 | 2013-06-13 | Amgen Inc. | Inhibiteurs aryle et hétéroaryle bicycliques des canaux calciques |
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9708288B2 (en) | 2012-04-27 | 2017-07-18 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
JP6189937B2 (ja) | 2012-04-27 | 2017-08-30 | ダウ アグロサイエンシィズ エルエルシー | 農薬組成物およびそれらに関する方法 |
US9282739B2 (en) | 2012-04-27 | 2016-03-15 | Dow Agrosciences Llc | Pesticidal compositions and processes related thereto |
WO2014023258A1 (fr) * | 2012-08-10 | 2014-02-13 | F.Hoffmann-La Roche Ag | Composés pyrazole carboxamides, compositions et procédés d'utilisation |
CN103073549A (zh) * | 2012-09-07 | 2013-05-01 | 苏州康润医药有限公司 | 3-溴吡唑啉[1,5-α]吡嘧啶-2-甲酸的合成工艺 |
BR112015004427A2 (pt) | 2012-10-26 | 2017-07-04 | Hoffmann La Roche | compostos , métodos para o tratamento de um estado inflamatório , da artrite reumatóide , da asma , de um distúrbio imunológico e de um distúrbio imune e composição farmacêutica |
EA201590930A1 (ru) | 2012-11-15 | 2015-08-31 | Инсайт Корпорейшн | Лекарственные формы руксолитиниба с замедленным высвобождением |
US9340546B2 (en) | 2012-12-07 | 2016-05-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2951590A1 (fr) | 2013-02-04 | 2015-12-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes d'analyse de l'activité jak2 dans des globules rouges sanguins et leurs utilisations |
CN105189509B (zh) | 2013-03-06 | 2017-12-19 | 因赛特公司 | 用于制备jak抑制剂的方法及中间体 |
WO2014143240A1 (fr) * | 2013-03-15 | 2014-09-18 | Vertex Pharmaceuticals Incorporated | Dérivés de pyrazolopyrimidine fusionnés utiles en tant qu'inhibiteurs de la kinase atr |
EP2970288A1 (fr) * | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Incorporated | Composés utiles en tant qu'inhibiteurs de la kinase atr |
EP2970289A1 (fr) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Composés utiles en tant qu'inhibiteurs de la kinase atr |
SI3030227T1 (sl) * | 2013-08-07 | 2020-08-31 | Incyte Corporation | Dozirne oblike s podaljšanim sproščanjem za inhibitor JAK1 |
US9102655B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
KR20160072155A (ko) | 2013-10-17 | 2016-06-22 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
JP2016536295A (ja) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
JP2016535010A (ja) | 2013-10-17 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
KR20160072154A (ko) | 2013-10-17 | 2016-06-22 | 다우 아그로사이언시즈 엘엘씨 | 살충성 화합물의 제조 방법 |
JP2016536296A (ja) | 2013-10-17 | 2016-11-24 | ダウ アグロサイエンシィズ エルエルシー | 有害生物防除性化合物の製造方法 |
CN105636446B (zh) | 2013-10-17 | 2018-07-13 | 美国陶氏益农公司 | 制备杀虫化合物的方法 |
EP3060055A4 (fr) | 2013-10-22 | 2017-03-29 | Dow AgroSciences LLC | Compositions pesticides synergiques et méthodes associées |
JP2016535025A (ja) | 2013-10-22 | 2016-11-10 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
TW201519780A (zh) | 2013-10-22 | 2015-06-01 | Dow Agrosciences Llc | 殺蟲組成物及相關方法(二) |
JP2016534086A (ja) | 2013-10-22 | 2016-11-04 | ダウ アグロサイエンシィズ エルエルシー | 相乗的有害生物防除組成物および関連する方法 |
AR098098A1 (es) | 2013-10-22 | 2016-05-04 | Dow Agrosciences Llc | Composiciones plaguicidas sinérgicas y métodos relacionados |
CN105848480A (zh) | 2013-10-22 | 2016-08-10 | 美国陶氏益农公司 | 协同杀虫组合物和相关方法 |
CA2927202A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides synergiques et methodes associees |
MX2016005323A (es) | 2013-10-22 | 2016-08-12 | Dow Agrosciences Llc | Composiciones pesticidas y metodos relacionados. |
CA2926438A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides et procedes associes |
EP3060052A4 (fr) | 2013-10-22 | 2017-04-05 | Dow AgroSciences LLC | Compositions pesticides synergiques et procédés associés |
US9808008B2 (en) | 2013-10-22 | 2017-11-07 | Dow Agrosciences Llc | Synergistic pesticidal compositions and related methods |
CN105828610B (zh) | 2013-10-22 | 2019-07-19 | 美国陶氏益农公司 | 杀虫组合物和与其相关的方法 |
MX2016005325A (es) | 2013-10-22 | 2016-08-08 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
WO2015061155A1 (fr) | 2013-10-22 | 2015-04-30 | Dow Agrosciences Llc | Compositions pesticides et procédés associés |
MX2016005316A (es) | 2013-10-22 | 2017-03-01 | Dow Agrosciences Llc | Composiciones pesticidas sinergicas y metodos relacionados. |
KR20160074621A (ko) | 2013-10-22 | 2016-06-28 | 다우 아그로사이언시즈 엘엘씨 | 상승작용적 살충 조성물 및 관련 방법 |
AU2014340430B2 (en) | 2013-10-22 | 2017-05-25 | Dow Agrosciences Llc | Pesticidal compositions and related methods |
TW201605847A (zh) * | 2013-11-08 | 2016-02-16 | 武田藥品工業股份有限公司 | 雜環化合物 |
CN104650092B (zh) * | 2013-11-16 | 2017-11-10 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
JP2016540773A (ja) * | 2013-12-06 | 2016-12-28 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
HUE046727T2 (hu) | 2013-12-06 | 2020-03-30 | Vertex Pharma | Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai |
TW201620911A (zh) * | 2014-03-17 | 2016-06-16 | 雷西肯製藥股份有限公司 | 銜接子關聯激酶1之抑制劑、包含其之組成物、及其使用方法 |
EA201691872A1 (ru) | 2014-03-19 | 2017-04-28 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения для применения в лечении pi3k-гамма-опосредованных расстройств |
US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
EA201692011A1 (ru) * | 2014-04-08 | 2017-01-30 | Инсайт Корпорейшн | Лечение b-клеточных злокачественных новообразований с применением комбинации ингибиторов jak и pi3k |
EP3145929B1 (fr) * | 2014-05-23 | 2021-01-13 | F. Hoffmann-La Roche AG | Composés 5-chloro -2-difluorométhoxyphényl pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
WO2015184305A1 (fr) | 2014-05-30 | 2015-12-03 | Incyte Corporation | Traitement de la leucémie neutrophile chronique (cnl) et de la leucémie myéloïde chronique atypique (acml) par des inhibiteurs de jak1 |
AU2015271030B2 (en) * | 2014-06-05 | 2019-05-16 | Vertex Pharmaceuticals Incorporated | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo [1,5-a] pyrimidin-3-carboxamide compound useful as ATR kinase inhibitor, the preparation of said compound and different solid forms thereof |
PL3157566T3 (pl) | 2014-06-17 | 2019-10-31 | Vertex Pharma | Metoda leczenia nowotworu przy użyciu kombinacji inhibitorów chk1 i atr |
EP3174856A4 (fr) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Procédé pour la préparation de 3-(3-chloro-1h-pyrazol-1-yl) pyridine |
EP3186229A4 (fr) | 2014-07-31 | 2018-01-10 | Dow AgroSciences LLC | Procédé pour la préparation de 3-(3-méthyl-phényl-1h-pyrazol-1-yl)pyridine |
CN106470976A (zh) | 2014-07-31 | 2017-03-01 | 美国陶氏益农公司 | 制备3‑(3‑氯‑1h‑吡唑‑1‑基)吡啶的方法 |
US9024031B1 (en) | 2014-08-19 | 2015-05-05 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
BR112017004613A2 (pt) | 2014-09-12 | 2017-12-05 | Dow Agrosciences Llc | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
WO2016202898A1 (fr) * | 2015-06-19 | 2016-12-22 | Bayer Pharma Aktiengesellschaft | Inhibiteurs de transport du glucose |
CN114230571A (zh) | 2015-09-14 | 2022-03-25 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 |
CN108473491A (zh) | 2015-11-06 | 2018-08-31 | 萨穆梅德有限公司 | 2-(1h-吲唑-3-基)-3h-咪唑并[4,5-c]吡啶以及其抗炎用途 |
TW201720828A (zh) * | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
WO2017140825A1 (fr) * | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Composés thérapeutiques, leurs compositions et méthodes d'utilisation |
WO2017161116A1 (fr) | 2016-03-17 | 2017-09-21 | Infinity Pharmaceuticals, Inc. | Isotopologues de composés isoquinolinone et quinazolinone et leurs utilisations comme inhibiteurs de la kinase pi3k |
WO2017214269A1 (fr) | 2016-06-08 | 2017-12-14 | Infinity Pharmaceuticals, Inc. | Composés hétérocycliques et leurs utilisations |
CN106008525B (zh) * | 2016-06-16 | 2018-08-07 | 南京工业大学 | 一种小分子有机纳米肿瘤光热治疗试剂及其制备方法 |
EP3562807B1 (fr) | 2016-12-29 | 2022-08-03 | Corteva Agriscience LLC | Procédés de préparation de composés pesticides |
WO2018125817A1 (fr) | 2016-12-29 | 2018-07-05 | Dow Agrosciences Llc | Procédés de préparation de composés pesticides |
RU2019123319A (ru) | 2016-12-29 | 2021-02-01 | Ф. Хоффманн-Ля Рош Аг | Пиразолопиримидины и способы их применения |
CN115925693A (zh) * | 2017-01-17 | 2023-04-07 | 阿斯利康(瑞典)有限公司 | Jak1选择性抑制剂 |
CN110494434B (zh) * | 2017-03-14 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 吡唑并氯苯基化合物、其组合物及其使用方法 |
WO2018167283A1 (fr) | 2017-03-17 | 2018-09-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Procédés pour le diagnostic et le traitement d'un remodelage neuronal associé à un adénocarcinome canalaire pancréatique |
US20200088732A1 (en) | 2017-04-13 | 2020-03-19 | INSERM (Institut National de la Santé et de la Recherche Mèdicale) | Methods for the diagnosis and treatment of pancreatic ductal adenocarcinoma |
PL233595B1 (pl) * | 2017-05-12 | 2019-11-29 | Celon Pharma Spolka Akcyjna | Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK |
AU2018274577A1 (en) * | 2017-05-22 | 2019-10-10 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
CN110678467B (zh) * | 2017-05-22 | 2023-06-13 | 豪夫迈·罗氏有限公司 | 治疗化合物和组合物及其使用方法 |
BR112020000964A2 (pt) | 2017-07-18 | 2020-07-14 | Bayer Cropscience Aktiengesellschaft | 3-heteroariloxi-1h-pirazóis substituídos e sais dos mesmos e seu uso como substâncias ativas herbicidas |
CN107686456B (zh) * | 2017-07-25 | 2018-10-23 | 杭州师范大学 | 一种喹喏酮关键中间体乙酯胺化物及其制备方法和应用 |
CN109422751B (zh) * | 2017-09-03 | 2022-04-22 | 上海美志医药科技有限公司 | 一类具有降解酪氨酸蛋白激酶jak3活性的化合物 |
TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
WO2019139714A1 (fr) | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Composés pyrazolopyrimidine utilisés en tant qu'inhibiteurs de jak |
SG11202006453SA (en) * | 2018-01-17 | 2020-08-28 | Glaxosmithkline Ip Dev Ltd | Pi4kiiibeta inhibitors |
MX2020007973A (es) | 2018-01-30 | 2020-12-07 | Incyte Corp | Procesos para preparar (1-(3-fluoro-2-(trifluorometil)isonicotinil )piperidin-4-ona). |
CN110476009A (zh) | 2018-03-07 | 2019-11-19 | 三菱化学株式会社 | 透明树脂组合物、树脂成型体、灯罩、车辆用灯罩、组合灯罩和车辆 |
CN113768934A (zh) | 2018-03-30 | 2021-12-10 | 因赛特公司 | 使用jak抑制剂治疗化脓性汗腺炎 |
AU2019252259A1 (en) * | 2018-04-13 | 2020-12-03 | Incyte Corporation | Biomarkers for graft-versus-host disease |
WO2020092015A1 (fr) | 2018-11-02 | 2020-05-07 | University Of Rochester | Atténuation thérapeutique d'une infection épithéliale |
WO2020150552A2 (fr) * | 2019-01-17 | 2020-07-23 | Samumed, Llc | Procédés de traitement de troubles du cartilage par inhibition de clk et dyrk |
CA3129665A1 (fr) | 2019-03-21 | 2020-09-24 | Onxeo | Molecule dbait associee a un inhibiteur de kinase pour le traitement du cancer |
WO2020257145A1 (fr) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs de sulfone pyrazolopyrimidine de jak kinases et leurs utilisations |
WO2020257143A1 (fr) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs éther-aryl-pyrazolopyrimidine de kinases jak et leurs utilisations |
WO2020257142A1 (fr) | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Inhibiteurs de pyrazolopyrimidine à substitution tétrazole de kinases jak et leurs utilisations |
EP4054579A1 (fr) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase |
WO2021148581A1 (fr) | 2020-01-22 | 2021-07-29 | Onxeo | Nouvelle molécule dbait et son utilisation |
US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
WO2022256358A1 (fr) | 2021-06-03 | 2022-12-08 | Genentech, Inc. | Procédé de préparation de médicaments |
CN115466227A (zh) * | 2022-06-30 | 2022-12-13 | 杭州国瑞生物科技有限公司 | 一种3-(氯甲基)-1-甲基-1h-1,2,4-三唑盐酸盐的制备方法 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES517193A0 (es) | 1981-11-10 | 1983-12-01 | Wellcome Found | Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina. |
US4602035A (en) | 1983-12-07 | 1986-07-22 | Hoechst-Roussel Pharmaceuticals Inc. | Antidepressant (3-aryl-2,3-dihydrobenzofuran-3-yl)alkylamines |
US4847256A (en) | 1986-10-16 | 1989-07-11 | American Cyanamid Company | 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines |
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
US5705625A (en) | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
US7070972B1 (en) | 1995-01-13 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Janus family kinases and identification of immune modulators |
US7091020B1 (en) | 1995-12-05 | 2006-08-15 | Incyte Corporation | Human Jak2 kinase |
ID18494A (id) | 1996-10-02 | 1998-04-16 | Novartis Ag | Turunan pirazola leburan dan proses pembuatannya |
US6235741B1 (en) | 1997-05-30 | 2001-05-22 | Merck & Co., Inc. | Angiogenesis inhibitors |
FR2791562B1 (fr) | 1999-03-29 | 2004-03-05 | Oreal | Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture |
EP1221444B1 (fr) | 1999-07-02 | 2005-08-31 | Eisai Co., Ltd. | Derives d'imidazole condenses et medicaments contre le diabete sucre |
PT1382339E (pt) * | 1999-12-10 | 2008-02-06 | Pfizer Prod Inc | Composições que contêm derivados de pirrolo[2,3-d]- pirimidina |
MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
CA2502429A1 (fr) | 2002-10-31 | 2004-05-21 | Amgen Inc. | Agents anti-inflammatoires |
AU2003299651A1 (en) | 2002-12-11 | 2004-06-30 | Merck And Co., Inc. | Tyrosine kinase inhibitors |
US20070270408A1 (en) | 2003-04-11 | 2007-11-22 | Novo Nordisk A/S | Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines |
EP1615697A2 (fr) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | Utilisation pharmaceutique de pyrazolo 1,5-a]pyrimidines substituees |
SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
US7393873B2 (en) * | 2003-07-02 | 2008-07-01 | Merck & Co., Inc. | Arylsulfonamide derivatives |
TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
GB0329214D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Novel compounds |
US7306631B2 (en) | 2004-03-30 | 2007-12-11 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
MXPA06011327A (es) * | 2004-03-30 | 2006-12-15 | Vertex Pharma | Azaindoles utiles como inhibidores de jak y otras proteinas cinasas. |
WO2005110477A2 (fr) | 2004-04-09 | 2005-11-24 | University Of South Florida | Polytherapies pour le cancer et des angiopathies proliferantes |
WO2005105803A2 (fr) | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Antagonistes du recepteur de l'adenosine a1 |
EP1765825A1 (fr) | 2004-06-25 | 2007-03-28 | Amgen Inc. | Triazols et indazols condenses convenant pour le traitement de maladies induites par les citokines et autres pathologies |
AU2005304784B2 (en) | 2004-11-04 | 2011-03-24 | Vertex Pharmaceuticals Incorporated | Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases |
US20100216798A1 (en) | 2005-07-29 | 2010-08-26 | Astellas Pharma Inc | Fused heterocycles as lck inhibitors |
WO2007039797A1 (fr) | 2005-10-03 | 2007-04-12 | Pfizer Products Inc. | Utilisation d'antagonistes du recepteur cannabinoide de type 1 pour traiter les inflammations et l'arthrite |
PE20070543A1 (es) * | 2005-10-06 | 2007-06-14 | Schering Corp | Pirazolopirimidinas como inhibidores de protein quinasas |
AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
AU2006304875B2 (en) | 2005-10-21 | 2013-01-17 | Exelixis, Inc. | Pyrazolo-pyrimidines as casein kinase II (CK2) modulators |
JP2009518340A (ja) | 2005-12-08 | 2009-05-07 | ノバルティス アクチエンゲゼルシャフト | EphBおよびVEGFR2キナーゼ阻害剤としてのピラゾロ[1,5−a]ピリジン−3−カルボン酸 |
US8541406B2 (en) | 2006-02-07 | 2013-09-24 | Nv Remynd | Thiadiazole derivatives for the treatment of neurodegenerative diseases |
TW200800997A (en) | 2006-03-22 | 2008-01-01 | Astrazeneca Ab | Chemical compounds |
EP2001884A1 (fr) * | 2006-04-05 | 2008-12-17 | Vertex Pharmaceuticals, Inc. | Désazapurines utiles comme inhibiteurs des kinases janus |
AU2007255864A1 (en) | 2006-06-02 | 2007-12-13 | Nippon Shinyaku Co., Ltd. | 9,10-secopregnane derivative and pharmaceutical |
AR061793A1 (es) | 2006-07-05 | 2008-09-24 | Mitsubishi Tanabe Pharma Corp | Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica |
PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
AU2007321924A1 (en) | 2006-11-20 | 2008-05-29 | Alantos Pharmaceuticals Holding, Inc. | Heterobicyclic metalloprotease inhibitors |
WO2009017954A1 (fr) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibiteurs de kinase jak2 |
ATE510827T1 (de) * | 2007-10-12 | 2011-06-15 | Ingenium Pharmaceuticals Gmbh | Inhibitoren von proteinkinasen |
WO2009073153A2 (fr) | 2007-11-28 | 2009-06-11 | Dana Farber Cancer Institute | Inhibiteurs myristate à petites molécules de bcr-abl et procédés d'utilisation |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
WO2010019762A1 (fr) | 2008-08-13 | 2010-02-18 | Jenrin Discovery | Composés de purine en tant que bloqueurs de récepteur aux cannabinoïdes |
PE20131197A1 (es) * | 2008-10-31 | 2013-11-06 | Genentech Inc | Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen |
WO2010063487A1 (fr) | 2008-12-05 | 2010-06-10 | Merz Pharma Gmbh & Co. Kgaa | Pyrazolopyrimidines, procédé pour leur préparation et leur utilisation comme médicament |
CA2748862A1 (fr) | 2009-02-06 | 2010-08-12 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Nouveaux composes heterocycliques bicycliques substitues en tant que modulateurs de la gamma-secretase |
TWI461425B (zh) | 2009-02-19 | 2014-11-21 | Janssen Pharmaceuticals Inc | 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類 |
UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
TW201125867A (en) | 2009-10-20 | 2011-08-01 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors |
MX2012010265A (es) | 2010-03-17 | 2012-10-01 | Hoffmann La Roche | Compuestos de imidazopiridina, composiciones y metodos de uso. |
JP2013525392A (ja) | 2010-04-30 | 2013-06-20 | セルゾーム リミティッド | Jak阻害剤としてのピラゾール化合物 |
-
2010
- 2010-02-07 UA UAA201201035A patent/UA110324C2/uk unknown
- 2010-07-02 IN IN755DEN2012 patent/IN2012DN00755A/en unknown
- 2010-07-02 CN CN201080039041.1A patent/CN102482284B/zh active Active
- 2010-07-02 EP EP10794815.0A patent/EP2448941B1/fr active Active
- 2010-07-02 US US13/382,145 patent/US8999998B2/en active Active
- 2010-07-02 WO PCT/US2010/040906 patent/WO2011003065A2/fr active Application Filing
- 2010-07-02 BR BRPI1010197A patent/BRPI1010197A2/pt not_active Application Discontinuation
- 2010-07-02 EP EP19211640.8A patent/EP3670514A1/fr not_active Withdrawn
- 2010-07-02 NZ NZ706218A patent/NZ706218A/en not_active IP Right Cessation
- 2010-07-02 SG SG10201509607XA patent/SG10201509607XA/en unknown
- 2010-07-02 SI SI201031625T patent/SI2448941T1/en unknown
- 2010-07-02 NZ NZ738778A patent/NZ738778A/en not_active IP Right Cessation
- 2010-07-02 KR KR1020187027109A patent/KR20180108858A/ko not_active Application Discontinuation
- 2010-07-02 DK DK10794815.0T patent/DK2448941T3/en active
- 2010-07-02 MA MA34594A patent/MA33502B1/fr unknown
- 2010-07-02 JP JP2012517917A patent/JP5769261B2/ja active Active
- 2010-07-02 RS RS20171278A patent/RS56671B1/sr unknown
- 2010-07-02 MX MX2012000169A patent/MX2012000169A/es active IP Right Grant
- 2010-07-02 CA CA2767097A patent/CA2767097A1/fr not_active Abandoned
- 2010-07-02 PL PL10794815T patent/PL2448941T3/pl unknown
- 2010-07-02 HU HUE10794815A patent/HUE035537T2/en unknown
- 2010-07-02 MY MYPI2011006384A patent/MY160156A/en unknown
- 2010-07-02 KR KR1020127002790A patent/KR101825754B1/ko active IP Right Grant
- 2010-07-02 LT LTEP10794815.0T patent/LT2448941T/lt unknown
- 2010-07-02 EP EP17192475.6A patent/EP3333169B1/fr active Active
- 2010-07-02 NZ NZ719972A patent/NZ719972A/en not_active IP Right Cessation
- 2010-07-02 PE PE2012000003A patent/PE20120575A1/es active IP Right Grant
- 2010-07-02 AU AU2010266188A patent/AU2010266188B2/en not_active Ceased
- 2010-07-02 CR CR20170115A patent/CR20170115A/es unknown
- 2010-07-02 RU RU2015133989A patent/RU2675857C2/ru not_active IP Right Cessation
- 2010-07-02 RU RU2012103487/04A patent/RU2567238C2/ru not_active IP Right Cessation
- 2010-07-02 NZ NZ622283A patent/NZ622283A/en not_active IP Right Cessation
- 2010-07-02 PE PE2015000692A patent/PE20151249A1/es not_active Application Discontinuation
- 2010-07-02 SG SG2011097623A patent/SG177454A1/en unknown
- 2010-07-02 PT PT107948150T patent/PT2448941T/pt unknown
- 2010-07-02 KR KR1020177012984A patent/KR101903305B1/ko active IP Right Grant
- 2010-07-02 NO NO10794815A patent/NO2448941T3/no unknown
- 2010-07-02 CN CN201510276276.7A patent/CN104910161B/zh active Active
- 2010-07-02 ES ES10794815.0T patent/ES2657839T3/es active Active
-
2011
- 2011-12-27 IL IL217224A patent/IL217224B/en not_active IP Right Cessation
-
2012
- 2012-01-02 CL CL2012000001A patent/CL2012000001A1/es unknown
- 2012-01-20 ZA ZA2012/00490A patent/ZA201200490B/en unknown
- 2012-01-25 CO CO12011326A patent/CO6491081A2/es active IP Right Grant
- 2012-01-30 CR CR20120053A patent/CR20120053A/es unknown
- 2012-02-02 EC ECSP12011645 patent/ECSP12011645A/es unknown
-
2013
- 2013-10-02 ZA ZA2013/07356A patent/ZA201307356B/en unknown
-
2015
- 2015-02-06 US US14/615,873 patent/US20150152117A1/en not_active Abandoned
- 2015-03-25 PH PH12015500666A patent/PH12015500666A1/en unknown
- 2015-06-17 JP JP2015122441A patent/JP6312634B2/ja active Active
- 2015-12-09 IL IL242999A patent/IL242999B/en not_active IP Right Cessation
-
2017
- 2017-06-20 US US15/627,847 patent/US20170283424A1/en not_active Abandoned
-
2018
- 2018-01-04 JP JP2018000305A patent/JP2018083828A/ja not_active Withdrawn
- 2018-01-15 IL IL256921A patent/IL256921A/en unknown
- 2018-01-26 HR HRP20180157TT patent/HRP20180157T1/hr unknown
-
2019
- 2019-06-07 JP JP2019106948A patent/JP2019194199A/ja active Pending
- 2019-09-05 US US16/561,432 patent/US20200002345A1/en not_active Abandoned
-
2022
- 2022-01-14 US US17/648,045 patent/US20220389020A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33502B1 (fr) | Composés pyrazolopyrimidine inhibiteurs des jak et procédés | |
WO2008005956A3 (fr) | Inhibiteurs de pyrrolotriazine kinase | |
DK1678166T3 (da) | Proteinkinaseinhibitorer | |
TW200613306A (en) | Imidazotriazines as protein kinase inhibitors | |
WO2006044497A3 (fr) | Composes de spiropiperidine utilises comme inhibiteurs de beta-secretase en vue du traitement de la maladie d'alzheimer | |
BRPI0417110A (pt) | inibidores de fosfodiesterase 4, incluindo análogos de diarilamina n-substituìdos, composto, composição farmacêutica, método para aumentar a cognição em um paciente no qual tal aumento é desejado, método de tratamento de um paciente que sofre de degeneração ou declìnio da cognição, método para o tratamento de um paciente que tem uma doença que envolve nìveis reduzidos de camp, método de inibição da atividade da enzima pde4 em uma paciente, método de tratamento de um paciente que sofre de degeneração da memória devido a uma doença neurodegenerativa, método de tratamento de um paciente que sofre de degeneração da memória devida a um distúrbio neurodegenerativo agudo, método de tratamento de um paciente que sofre de uma doença alérgica ou inflamatória, método para o tratamento de um paciente que sofre de esquizofrenia, método para o tratamento de um paciente que sofre de psicose caracterizada por nìveis elevados pde4, sendo que a dita psicose é uma forma de depressão | |
MA30075B1 (fr) | Derives de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
TNSN07349A1 (fr) | Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur | |
MA31466B1 (fr) | Derives de benzimidazole | |
TN2009000138A1 (fr) | Biaryl-ether-urees | |
NO20062136L (no) | Imidazopyrazintyrosin-kinaseinhibitorer | |
MA31373B1 (fr) | Composes amino-heterocycliques | |
MA30781B1 (fr) | Inhibiteur de kinase | |
YU84603A (sh) | Novi inhibitori tirozin kinaze | |
MA31655B1 (fr) | Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt. | |
BG106020A (en) | Inhibitors of impdh enzyme | |
MA27781A1 (fr) | 3-fluoro-piperidines comme antagonistes de nmda/nr2b. | |
WO2007011833A3 (fr) | Inhibiteurs de spiropiperidine beta-secretase pour le traitement de la maladie d'alzheimer | |
MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
MXPA03011484A (es) | Heteroarilos multiciclicos sustituidos con quinuclidinas para el tratamiento de enfermedades. | |
SG170101A1 (en) | 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. | |
MA32009B1 (fr) | Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux | |
MA30723B1 (fr) | Benzoxazoles et oxazolopyridines utiles en tant qu'inhibiteurs des janus kinases. | |
MA31919B1 (fr) | Composés inhibiteurs de la dipeptidyl peptidase-iv, leurs procédés de préparation, et compositions pharmaceutiques contenant ces composés comme agent actif | |
ZA200704913B (en) | 3-[2-(3-acylamino-2-oxo-2H-pyridin-1-YL)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |